Blood-Brain Barrier Integrity and Clearance of Amyloid-β from the BBB

被引:43
|
作者
Cockerill, Irsalan [1 ]
Oliver, Joy-Anne [1 ]
Xu, Huaxi [2 ,3 ]
Fu, Bingmei M. [4 ]
Zhu, Donghui [1 ]
机构
[1] Univ North Texas, Dept Biomed Engn, Denton, TX 76203 USA
[2] Xiamen Univ, Fujian Prov Key Lab Neurodegenerat Dis & Aging Re, Inst Neurosci, Coll Med, Xiamen, Fujian, Peoples R China
[3] Sanford Burnham Prebys Med Discovery Inst, Degenerat Dis Program, La Jolla, CA USA
[4] CUNY City Coll, Dept Biomed Engn, New York, NY 10031 USA
来源
MOLECULAR, CELLULAR, AND TISSUE ENGINEERING OF THE VASCULAR SYSTEM | 2018年 / 1097卷
关键词
ALUMINUM;
D O I
10.1007/978-3-319-96445-4_14
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Alzheimer's disease, a type of dementia, affects memory, behavior, and cognitive processes in affected individuals. It is one of the prominent diseases, accounting for 60-80% of dementia cases and affecting a significant population of persons over the age of 65 years. While rare, Alzheimer's disease (AD) may affect the younger population as well. With such a widespread number of persons affected with AD, scientists have undertaken the initiative to develop a cure for this devastating disease; however, it has been deemed quite challenging. A dysfunctional blood-brain barrier, with impaired ability to clear amyloid-beta from the brain, has been directly linked to the development of Alzheimer's disease. The blood-brain barrier restricts the flow of many substances into and out of the brain and serves as a selective and protective barrier to the brain. A proper functioning blood-brain barrier contributes to the maintenance and integrity of the brain. In turn, different systems and mechanisms within the blood-brain barrier are set in place to facilitate mediated passage of materials and substances between the brain and the bloodstream. In relation to AD, the mediation of amyloid-beta clearance is of great importance in maintaining the blood-brain barrier's integrity.
引用
收藏
页码:261 / 278
页数:18
相关论文
共 50 条
  • [1] Autoregulated paracellular clearance of amyloid-β across the blood-brain barrier
    Keaney, James
    Walsh, Dominic M.
    O'Malley, Tiernan
    Hudson, Natalie
    Crosbie, Darragh E.
    Loftus, Teresa
    Sheehan, Florike
    McDaid, Jacqueline
    Humphries, Marian M.
    Callanan, John J.
    Brett, Francesca M.
    Farrell, Michael A.
    Humphries, Peter
    Campbell, Matthew
    SCIENCE ADVANCES, 2015, 1 (08):
  • [2] Blood-brain barrier integrity impacts the use of plasma amyloid-β as a proxy of brain amyloid-β pathology
    Bellaver, Bruna
    Puig-Pijoan, Albert
    Ferrari-Souza, Joo Pedro
    Leffa, Douglas T.
    Lussier, Firoza Z.
    Ferreira, Pamela C. L.
    Tissot, Cecile
    Povala, Guilherme
    Therriault, Joseph
    Benedet, Andrea L.
    Ashton, Nicholas J.
    Servaes, Stijn
    Chamoun, Mira
    Stevenson, Jenna
    Rahmouni, Nesrine
    Vermeiren, Marie
    Macedo, Arthur C.
    Fernandez-Lebrero, Aida
    Garcia-Escobar, Greta
    Navalpotro-Gomez, Irene
    Lopez, Oscar
    Tudorascu, Dana L.
    Cohen, Ann
    Villemagne, Victor L.
    Klunk, William E.
    Gauthier, Serge
    Zimmer, Eduardo R.
    Karikari, Thomas K.
    Blennow, Kaj
    Zetterberg, Henrik
    Suarez-Calvet, Marc
    Rosa-Neto, Pedro
    Pascoal, Tharick A.
    ALZHEIMERS & DEMENTIA, 2023, 19 (09) : 3815 - 3825
  • [3] Central role for PICALM in amyloid-β blood-brain barrier transcytosis and clearance
    Zhao, Zhen
    Sagare, Abhay P.
    Ma, Qingyi
    Halliday, Matthew R.
    Kong, Pan
    Kisler, Kassandra
    Winkler, Ethan A.
    Ramanathan, Anita
    Kanekiyo, Takahisa
    Bu, Guojun
    Owens, Nelly Chuqui
    Rege, Sanket V.
    Si, Gabriel
    Ahuja, Ashim
    Zhu, Donghui
    Miller, Carol A.
    Schneider, Julie A.
    Maeda, Manami
    Maeda, Takahiro
    Sugawara, Tohru
    Ichida, Justin K.
    Zlokovic, Berislav V.
    NATURE NEUROSCIENCE, 2015, 18 (07) : 978 - +
  • [4] Central role for PICALM in amyloid-β blood-brain barrier transcytosis and clearance
    Zhen Zhao
    Abhay P Sagare
    Qingyi Ma
    Matthew R Halliday
    Pan Kong
    Kassandra Kisler
    Ethan A Winkler
    Anita Ramanathan
    Takahisa Kanekiyo
    Guojun Bu
    Nelly Chuqui Owens
    Sanket V Rege
    Gabriel Si
    Ashim Ahuja
    Donghui Zhu
    Carol A Miller
    Julie A Schneider
    Manami Maeda
    Takahiro Maeda
    Tohru Sugawara
    Justin K Ichida
    Berislav V Zlokovic
    Nature Neuroscience, 2015, 18 : 978 - 987
  • [5] Etodolac Enhances the Blood-Brain Barrier Integrity and Clearance of Amyloid-Beta
    Elfakhri, Khaled
    Keller, Jeffrey N.
    Kaddoumi, Amal
    2016 32ND SOUTHERN BIOMEDICAL ENGINEERING CONFERENCE (SBEC), 2016, : 94 - 94
  • [6] Author Correction: Central role for PICALM in amyloid-β blood-brain barrier transcytosis and clearance
    Zhen Zhao
    Abhay P. Sagare
    Qingyi Ma
    Matthew R. Halliday
    Pan Kong
    Kassandra Kisler
    Ethan A. Winkler
    Anita Ramanathan
    Takahisa Kanekiyo
    Guojun Bu
    Nelly Chuqui Owens
    Sanket V. Rege
    Gabriel Si
    Ashim Ahuja
    Donghui Zhu
    Carol A. Miller
    Julie A. Schneider
    Manami Maeda
    Takahiro Maeda
    Tohru Sugawara
    Justin K. Ichida
    Berislav V. Zlokovic
    Nature Neuroscience, 2024, 27 : 208 - 208
  • [7] Examination of blood-brain barrier (BBB) integrity in a mouse brain tumor model
    On, Ngoc H.
    Mitchell, Ryan
    Savant, Sanjot D.
    Bachmeier, Corbin. J.
    Hatch, Grant M.
    Miller, Donald W.
    JOURNAL OF NEURO-ONCOLOGY, 2013, 111 (02) : 133 - 143
  • [8] Examination of blood-brain barrier (BBB) integrity in a mouse brain tumor model
    Ngoc Hong On
    Mitchell, Ryan
    Savant, Sanjot
    Miller, Donald Wayne
    FASEB JOURNAL, 2008, 22
  • [9] Examination of blood-brain barrier (BBB) integrity in a mouse brain tumor model
    On, Ngoc Hong
    Mitchell, Ryan
    Savant, Sanjot
    Miller, Donald Wayne
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2008, 67 (05): : 507 - 508
  • [10] Clearance of Amyloid-β Peptide Across the Blood-Brain Barrier: Implication for Therapies in Alzheimer's Disease
    Deane, R.
    Bell, R. D.
    Sagare, A.
    Zlokovic, B. V.
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2009, 8 (01) : 16 - 30